Krystal Biotech (NASDAQ:KRYS) Stock Keeps “Buy” Rating at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 9.39% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Bank of America upped their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a report on Monday, September 21st. Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, TD Cowen upped their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $377.20.

Krystal Biotech Stock Down 0.2%

NASDAQ:KRYS traded down $0.69 during mid-day trading on Thursday, hitting $330.00. 283,921 shares of the stock traded hands, compared to its average volume of 328,538. The stock has a market capitalization of $9.77 billion, a price-to-earnings ratio of 41.35 and a beta of 0.50. Krystal Biotech has a 52 week low of $183.03 and a 52 week high of $382.54. The firm’s 50 day moving average is $340.46 and its two-hundred day moving average is $322.60.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, research analysts predict that Krystal Biotech will post 7.47 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the stock. Terra Nova Asset Management LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $828,000. GK Wealth Management LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $59,000. GAMMA Investing LLC boosted its position in Krystal Biotech by 10.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock valued at $366,000 after buying an additional 102 shares during the period. Toth Financial Advisory Corp boosted its position in Krystal Biotech by 9.5% in the 3rd quarter. Toth Financial Advisory Corp now owns 4,941 shares of the company’s stock valued at $1,643,000 after buying an additional 430 shares during the period. Finally, Congress Asset Management Co. boosted its position in Krystal Biotech by 34.8% in the 3rd quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock valued at $17,986,000 after buying an additional 13,949 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.